|
|
Abstract
Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1-infected children: 3 years of follow-up
B. Larrú1, S. Resino2, J.M. Bellón2, R. Resino2, M.D. Gurbindo3, J.A. Leon4, J.T. Ramos5, L. Ciria6, M.I. De José1, M.J. Mellado7, M.A. Muñoz2
Background: antiretroviral treatment in children has special features and consequently, results obtained from clinical trials with antiretroviral drugs in adults may not be representative of children. Nelfinavir (NFV) is a selective HIV-1 PI which has become as one of the first choices of PI for ART in children. We studied during a 3-year follow-up period the effects of highly active antiretroviral therapy with nelfinavir in vertically hiv-1 infected children.
Methods: Forty-two vertically HIV-infected children on HAART with NFV were involved in a multicentre prospective study. The children were monitored at least every 3 months with physical examinations, and blood sample collection to measure VL and CD4+ cell count. We performed a logistic regression analysis to determinate the odds ratio of baseline characteristics on virological or therapeutical failure.
Results: Very important increase in CD4+ was observed and VL decreased quickly and it remained low during the follow-up study. Children with CD4+ <25% at baseline achieved CD4+ >25% at 9 months of follow-up. HIV-infected children who achieved uVL were less than 40% in each visits during follow-up. Nevertheless, HIV-infected children with VL >5000 copies/ml were less than 50% during the follow-up study. Only baseline VL was an important factor to predict VL control during follow-up. Virological failure at defined end-point was confirmed in 30/42 patients. Along the whole of follow-up, 16/42 children stopped HAART with NFV. Baseline characteristics were not associated with therapeutic change.
Conclusions: NFV is a safe drug with a good profile and active to achieve a significant response in HIV-1 infected children. More studies which include strategies as TDM or resistance test, are needed to evaluate the use of this drug in pediatric population.
AIDS 2006 - XVI International AIDS Conference
Abstract no.
CDB0397
Suggested Citation
"B.Larrú, et al.
Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1-infected children: 3 years of follow-up.
:
AIDS 2006 - XVI International AIDS Conference:
Abstract no.
CDB0397"
|
|
|